Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.0c01065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[New therapeutic approaches for the treatment of primary biliary cholangitis].
Med Sci (Paris)
September 2025
Service des maladies de l'appareil digestif. Centre de compétence Maladies rares « Maladies inflammatoires des voies biliaires et hépatites autoimmunes », Hôpital Huriez, Lille, France.
Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC.
View Article and Find Full Text PDFClostridial-dominated gut microbiota promotes 7α-dehydroxylation of obeticholic acid to lithocholic acid in cholestasis treatment.
Biochem Biophys Res Commun
August 2025
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Avenue, Nanjing 210023, China. Electronic address:
Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist used in the treatment of liver diseases associated with cholestasis, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). However, its clinical utility is limited by dose-dependent hepatotoxicity, and the precise mechanism underlying OCA toxicity remains unclear. In this study, we investigated the mechanistic link between cholestasis-induced gut dysbiosis and OCA-associated hepatotoxicity.
View Article and Find Full Text PDFBile acids in metabolic dysfunction-associated steatotic liver disease.
World J Hepatol
August 2025
Department of Internal Medicine, Cantonal Hospital Safet Mujić Mostar, Mostar 88000, Bosnia and Herzegovina.
The liver is a central metabolic organ that regulates numerous physiological processes, including glucose and lipid metabolism, detoxification, and the synthesis of essential proteins and bile. Bile acids (BAs), synthesized from cholesterol in hepatocytes, not only facilitate the emulsification and absorption of dietary fats but also act as potent signaling molecules through receptors such as the farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally, closely linked with obesity, insulin resistance, and other components of metabolic syndrome.
View Article and Find Full Text PDFIMM-H007 promotes hepatic cholesterol and triglyceride metabolism by activating AMPK to attenuate hypercholesterolemia.
Acta Pharm Sin B
August 2025
State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Hypercholesterolemia is a significant risk factor for the development of atherosclerosis. 2',3',5'-Tri--acetyl- -(3-hydroxyphenyl) adenosine (IMM-H007), a novel AMPK agonist, has shown protective effects in metabolic diseases. However, its impact on cholesterol and triglyceride metabolism in hypercholesterolemia remains unclear.
View Article and Find Full Text PDFIntrahepatic Cholestasis of Pregnancy: Diagnosis, Management, and Future Directions-A Review of the Literature.
Diagnostics (Basel)
August 2025
Department of Obstetrics and Gynecology, Medical University of Warsaw, 02-091 Warsaw, Poland.
Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder specific to pregnancy, typically presenting in the third trimester. It is characterized by pruritus, elevated serum bile acids, and abnormal liver function tests. While maternal symptoms resolve postpartum, ICP poses significant risks to fetal health, including spontaneous preterm labor, meconium-stained amniotic fluid, and stillbirth.
View Article and Find Full Text PDF